Brivaracetam is an orally bioavailable levetiracetam derivative, with anticonvulsant activity. Brivaracetam is used in the treatment of partial-onset seizures. Brivaracetam was approval on February 19, 2016.
SynZeal offers all Brivaracetam related impuritiesstandards with certified COA and characterization data like IR, Mass, HPLC, purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Brivaracetam related standards are being used by major pharmaceuticalcompanies across the globe for their ANDA/DMF filing.
